GlassScriptPhysician profile
William M Adler
NPI 1710918610
$2,772.71
in general payments reported to CMS, 2019-2025
19 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $40.41 · 2021: $1,990 · 2022: $41.91 · 2023: $52.11 · 2024: $129 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540 · Education: $48.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.76 |
| Education | $48.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,950.00 | 2021 | |
| Janssen Biotech, INC. | $144.48 | 2020-2025 | Darzalex, Imbruvica, Talvey |
| E.R. Squibb & Sons, L.L.C. | $102.08 | 2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $100.00 | 2019 | |
| Gilead Sciences, INC. | $92.82 | 2021-2025 | Trodelvy |
| Pfizer INC. | $71.24 | 2023-2024 | |
| Seagen INC. | $42.20 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $39.22 | 2025 | |
| Stemline Therapeutics INC. | $34.12 | 2025 | Orserdu |
| Servier Pharmaceuticals LLC | $32.04 | 2025 | |
| Merck Sharp & Dohme LLC | $30.33 | 2025 | Keytruda Qlex, Keytruda |
| Daiichi Sankyo INC. | $27.11 | 2025 | Enhertu |
| Genzyme Corporation | $22.62 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.79 | 2024 | Enhertu |
| Fennec Pharmaceuticals, INC. | $18.61 | 2024 | Pedmark |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.43 | 2025 | Xtandi |
| Foundation Medicine, INC. | $13.58 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.